LondonAngiogenin, a blood-vessel protein, processes mitochondrial RNA.
The protein relocates to mitochondria during cell fusion, driving the energy ramp-up that allows muscle and bone-resorbing cells to merge.
Defects in the protein impair muscle regeneration and bone remodeling — 2 targets for future drug development.
Sources: Nature